Novabay Pharmaceuticals Stock Performance
| NBY Stock | USD 0.68 0.04 5.56% |
On a scale of 0 to 100, NovaBay Pharmaceuticals holds a performance score of 6. The company secures a Beta (Market Risk) of -0.45, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NovaBay Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, NovaBay Pharmaceuticals is likely to outperform the market. Please check NovaBay Pharmaceuticals' semi variance, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether NovaBay Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in NovaBay Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental drivers, NovaBay Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:35 | Last Split Date 2024-05-31 |
1 | Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer | 09/03/2024 |
2 | NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets | 09/20/2024 |
3 | Contrasting Roche NovaBay Pharmaceuticals | 10/17/2024 |
4 | Verve Therapeutics Reports Q3 Loss, Tops Revenue Estimates | 11/05/2024 |
5 | NovaBay GAAP EPS of -0.60 misses by 0.30, revenue of 2.44M misses by 0.19M | 11/08/2024 |
6 | NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 | 11/22/2024 |
| Begin Period Cash Flow | 5.8 M |
NovaBay |
NovaBay Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 52.00 in NovaBay Pharmaceuticals on August 26, 2024 and sell it today you would earn a total of 16.00 from holding NovaBay Pharmaceuticals or generate 30.77% return on investment over 90 days. NovaBay Pharmaceuticals is generating 0.6477% of daily returns assuming volatility of 7.5324% on return distribution over 90 days investment horizon. In other words, 67% of stocks are less volatile than NovaBay, and above 88% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
NovaBay Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NovaBay Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NovaBay Pharmaceuticals, and traders can use it to determine the average amount a NovaBay Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.086
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NBY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.53 actual daily | 67 67% of assets are less volatile |
Expected Return
| 0.65 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average NovaBay Pharmaceuticals is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NovaBay Pharmaceuticals by adding it to a well-diversified portfolio.
NovaBay Pharmaceuticals Fundamentals Growth
NovaBay Stock prices reflect investors' perceptions of the future prospects and financial health of NovaBay Pharmaceuticals, and NovaBay Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NovaBay Stock performance.
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 3.82 M | ||||
| Shares Outstanding | 4.89 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 3.12 X | ||||
| Price To Sales | 0.25 X | ||||
| Revenue | 14.73 M | ||||
| Gross Profit | 5.64 M | ||||
| EBITDA | (4.8 M) | ||||
| Net Income | (9.64 M) | ||||
| Cash And Equivalents | 5.36 M | ||||
| Cash Per Share | 0.07 X | ||||
| Total Debt | 2.74 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (4.13 M) | ||||
| Earnings Per Share | (74.61) X | ||||
| Market Capitalization | 3.33 M | ||||
| Total Asset | 9.03 M | ||||
| Retained Earnings | (174.85 M) | ||||
| Working Capital | 2.88 M | ||||
| Current Asset | 4.53 M | ||||
| Current Liabilities | 4.63 M | ||||
About NovaBay Pharmaceuticals Performance
Evaluating NovaBay Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NovaBay Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NovaBay Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 153.73 | 146.04 | |
| Return On Tangible Assets | (1.07) | (1.12) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (1.07) | (1.12) | |
| Return On Equity | (2.91) | (3.05) |
Things to note about NovaBay Pharmaceuticals performance evaluation
Checking the ongoing alerts about NovaBay Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NovaBay Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NovaBay Pharmaceuticals is way too risky over 90 days horizon | |
| NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock | |
| NovaBay Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| NovaBay Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 14.73 M. Reported Net Loss for the year was (9.64 M) with profit before taxes, overhead, and interest of 5.64 M. | |
| NovaBay Pharmaceuticals has about 5.36 M in cash with (4.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07. | |
| NovaBay Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 |
- Analyzing NovaBay Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NovaBay Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining NovaBay Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NovaBay Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NovaBay Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NovaBay Pharmaceuticals' stock. These opinions can provide insight into NovaBay Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.